VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Markman on PCP Awareness of Long-Term Side Effects

Maurie Markman, MD
Published: Wednesday, May 16, 2012

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.

The survey demonstrated that many PCPs are not familiar with the recognized LEs of common chemotherapy drugs for colorectal and breast cancers. Markman notes that as the population of cancer survivors continues to grow, PCPs will become increasingly responsible for follow-up care.

The survey looked at a nationally representative sample of 1072 PCPs and 1130 oncologists and found that nearly all oncologists (95.3%) in the survey were able to identify LEs. In contrast, only half of PCPs recognized cardiac dysfunction as a result of Adriamycin and just over 21% connected peripheral neuropathy with oxaliplatin and Taxol.

The expressed lack of PCP knowledge of LEs is a recognizable defect, Markman notes. The survey demonstrates that additional education is necessary, in order for PCPs to be able to adequately identify LEs in cancer survivors.

<<< View more from the 2012 ASCO Conference

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.

The survey demonstrated that many PCPs are not familiar with the recognized LEs of common chemotherapy drugs for colorectal and breast cancers. Markman notes that as the population of cancer survivors continues to grow, PCPs will become increasingly responsible for follow-up care.

The survey looked at a nationally representative sample of 1072 PCPs and 1130 oncologists and found that nearly all oncologists (95.3%) in the survey were able to identify LEs. In contrast, only half of PCPs recognized cardiac dysfunction as a result of Adriamycin and just over 21% connected peripheral neuropathy with oxaliplatin and Taxol.

The expressed lack of PCP knowledge of LEs is a recognizable defect, Markman notes. The survey demonstrates that additional education is necessary, in order for PCPs to be able to adequately identify LEs in cancer survivors.

<<< View more from the 2012 ASCO Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x